A Panel of Tumor-associated Autoantibodies for the Detection of Early-stage Breast Cancer

Hong, Chao‐Qun; Weng, Xuefen; Huang, Xu‐Chun; Chu, Ling-Yu; Wei, Lai‐Feng; Lin, Yiwei; Chen, Liu-Yi; Liu, Can-Tong; Xu, Yi‐Wei; Peng, Yu‐Hui

doi:10.7150/jca.57019

Cited by 12 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, tumor-associated (TA) autoantibodies are more abundant than their respective antigens and could be detected in cancer patients well before the tumor associated antigens accumulate to detectable levels [ 10 , 275 ], implying that the analysis of TA autoantibodies could be a valuable method for improving current early cancer detection approaches. Several studies have investigated the utility of TA autoantibodies in the early detection of epithelial malignancies such as breast cancer, lung cancer, and ovarian cancer [ 276 , 277 , 278 , 279 , 280 ]. In addition, there are reports suggesting the abundance of TA autoantibodies in PDAC, CRC, and prostate cancer patients [ 281 , 282 , 283 ].…”

Section: Mucin Autoantibodies For Early Cancer Detectionmentioning

confidence: 99%

Mucins as Potential Biomarkers for Early Detection of Cancer

Gautam

Κhan

Gopalakrishnan

et al. 2023

Cancers

View full text Add to dashboard Cite

Early detection significantly correlates with improved survival in cancer patients. So far, a limited number of biomarkers have been validated to diagnose cancers at an early stage. Considering the leading cancer types that contribute to more than 50% of deaths in the USA, we discuss the ongoing endeavors toward early detection of lung, breast, ovarian, colon, prostate, liver, and pancreatic cancers to highlight the significance of mucin glycoproteins in cancer diagnosis. As mucin deregulation is one of the earliest events in most epithelial malignancies following oncogenic transformation, these high-molecular-weight glycoproteins are considered potential candidates for biomarker development. The diagnostic potential of mucins is mainly attributed to their deregulated expression, altered glycosylation, splicing, and ability to induce autoantibodies. Secretory and shed mucins are commonly detected in patients’ sera, body fluids, and tumor biopsies. For instance, CA125, also called MUC16, is one of the biomarkers implemented for the diagnosis of ovarian cancer and is currently being investigated for other malignancies. Similarly, MUC5AC, a secretory mucin, is a potential biomarker for pancreatic cancer. Moreover, anti-mucin autoantibodies and mucin-packaged exosomes have opened new avenues of biomarker development for early cancer diagnosis. In this review, we discuss the diagnostic potential of mucins in epithelial cancers and provide evidence and a rationale for developing a mucin-based biomarker panel for early cancer detection.

show abstract

Section: Mucin Autoantibodies For Early Cancer Detectionmentioning

confidence: 99%

Mucins as Potential Biomarkers for Early Detection of Cancer

Gautam

Κhan

Gopalakrishnan

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…NY-ESO-1 autoantibodies have also been used in several studies for screening for breast cancer ( 38 , 62 ). However, its sensitivity is very low, since only about 7% of breast cancer patients have positive serum NY-ESO-1 autoantibodies ( 34 , 107 ).…”

Section: Autoantibodies As Biomarkers For Breast Cancermentioning

confidence: 99%

Autoantibodies as biomarkers for breast cancer diagnosis and prognosis

Yang

Han

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Breast cancer is the most common cancer in women worldwide and is a substantial public health problem. Screening for breast cancer mainly relies on mammography, which leads to false positives and missed diagnoses and is especially non-sensitive for patients with small tumors and dense breasts. The prognosis of breast cancer is mainly classified by tumor, node, and metastasis (TNM) staging, but this method does not consider the molecular characteristics of the tumor. As the product of the immune response to tumor-associated antigens, autoantibodies can be detected in peripheral blood and can be used as noninvasive, presymptomatic, and low-cost biomarkers. Therefore, autoantibodies can provide a possible supplementary method for breast cancer screening and prognosis classification. This article introduces the methods used to detect peripheral blood autoantibodies and the research progress in the screening and prognosis of breast cancer made in recent years to provide a potential direction for the examination and treatment of breast cancer.

show abstract

“…In addition, TAAbs have the advantages of being able to exist in the patient’s blood for a long time, being easy to detect, and the detection process being minimally invasive to the patient, and may be used as new diagnostic biomarkers for early cancer patients [ 8 – 10 ]. TAAb may be helpful for the early diagnosis of various solid tumors, such as esophageal cancer [ 11 ], lung cancer [ 12 ], breast cancer [ 13 ], hepatocellular carcinoma [ 14 ], colorectal cancer [ 15 ], thyroid cancer [ 16 ] and gastric cancer [ 17 ] and so on. Compared to the study of autoantibodies in the diagnosis of other cancers, the study of autoantibodies in the detection of OSCC is limited.…”

Section: Introductionmentioning

confidence: 99%

Identification of novel tumor-associated antigens and evaluation of a panel of autoantibodies in detecting oral cancer

Xie,

Sun,

Xia

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background We aimed to identify tumor-associated antigen (TAA) biomarkers through bioinformatic analysis and experimental verification, and to evaluate a panel of autoantibodies against tumor-associated antigens (TAAbs) for the detection of oral cancer (OC). Methods GEO and TCGA databases were used to screen significantly up-regulated genes related to OC, and protein-protein interaction (PPI) analysis and Cystoscope software were used to identify key genes. Enzyme-linked immunosorbent assay (ELISA) was used to detect the expression levels of autoantibodies in 173 OC patients and 173 normal controls, and binary logistic regression analysis was used to build a diagnostic model. Results Using bioinformatics, we identified 10 key genes (AURKA, AURKB, CXCL8, CXCL10, COL1A1, FN1, FOXM1, MMP9, SPP1 and UBE2C) that were highly expressed in OC. Three autoantibodies (anti-AURKA, anti-CXCL10, anti-FOXM1) were proven to have diagnostic value for OC in the verification set and the validation set. The combined assessment of these three autoantibodies improved the diagnostic value for OC, with an area under the curve (AUC), sensitivity and specificity of 0.741(95%CI:0.690–0.793),58.4% and 80.4%, respectively. In addition, the combination of these three autoantibodies also had high diagnostic value for oral squamous cell carcinoma (OSCC), with an AUC, sensitivity and specificity of 0.731(95%CI:0.674,0.786), 53.8% and 82.1%, respectively. Conclusions Our study revealed that AURKA, CXCL10 and FOXM1 may be potential biomarkers and the panel of three autoantibodies (anti-AURKA, anti-CXCL10 and anti-FOXM1) had good diagnostic value for OC.

show abstract

A Panel of Tumor-associated Autoantibodies for the Detection of Early-stage Breast Cancer

Cited by 12 publications

References 39 publications

Mucins as Potential Biomarkers for Early Detection of Cancer

Mucins as Potential Biomarkers for Early Detection of Cancer

Autoantibodies as biomarkers for breast cancer diagnosis and prognosis

Identification of novel tumor-associated antigens and evaluation of a panel of autoantibodies in detecting oral cancer

Contact Info

Product

Resources

About